Researchers at the National Eye Institute (NEI) have discovered a novel therapeutic strategy of using one or more selective estrogen-receptor modulators (SERMs), which may include the FDA-approved drug, Tamoxifen, for treating retinal degenerative diseases, like retinitis pigmentosa (RP) and age-related degeneration (AMD). SERMs exert their specific protection on photoreceptor degeneration likely by inhibiting microglial activation.
The National Eye Institute (NEI) seek research co-development or licensees for advancing AAV8/9-based therapies for X-linked forms of retinitis pigmentosa (XLRP) caused by mutations in RPGR (retinitis pigmentosa GTPase regulator) or RP2 (retinitis pigmentosa 2) gene.
Hibernation in mammals is a seasonal state of metabolic suppression and dormancy characterized by a decrease in body temperature to survive extreme environmental stresses. A new Induced Pluripotent Stem Cell (iPSC) line has been established from the neural precursor cells of wild type thirteen-lined ground squirrel (Spermophilus tridecemlineatus), a small mammalian hibernator with unique metabolic adaptations for coping with cold and restricted food supply. This ground squirrel iPSC line can be differentiated into many different cell types for hibernation studies, disease modeling, and drug screening for neuronal injuries or other diseases.
The National Eye Institute (NEI) seeks research co-development or licensees for making research- or clinical-grade preservation solutions for cold-sensitive organ transplantation or protection of brain injury or trauma during surgery.
Researchers at the National Eye Institute (NEI) have developed a novel therapeutic strategy of using recombinant IL-24 protein to treat inflammatory diseases that involve the proinflammatory T-helper 17 cell (Th17) response, such as uveitis, multiple sclerosis, rheumatoid arthritis, and Crohn’s disease. Researchers at the NEI seek licensing and/or co-development research collaborations for co-developing this technology as strategic partners or licensing it for commercialization.
Researchers at the National Institute of Health (NIH) and National Institute of Standards and Technology (NIST) seek licensing or co-development partners for a method to predict functions, identity, disease state, and health of stem cells using machine learning.
Scientists at the National Eye Institute (NEI) have developed a technology for a 3D bioprinting process. Through the process, an artificial blood retinal barrier (BRB) is constructed that may be used as a graft to potentially replace BRB tissues that are lost or damaged in many ocular disorders. The printed tissue structures might be therapeutically useful for grafts or as model systems to test function and physiological responses to drugs or other variables introduced into the system.
Researchers at the National Eye Institute (NEI) developed a surgical tool to place tissue into position in the retina. The NEI seeks co-development or licensing to commercialize a prototype already in pre-manufacturing. Alternative uses will be considered.
The National Eye Institute (NEI) and National Institute of Arthritis and Muscoskeletal and Skin Diseases (NIAMS) seeks licensing and/or co-development of a method of producing human retinal pigment epithelial (RPE) cells from human induced pluripotent stem cells (iPSCs).
This surgical clamp device is particularly useful for intraocular surgeries requiring incision in the sclera. The device provides ease of use for repeated opening and closure of an incision or wound for entry of instruments into the eye. It maintains precise alignment of the wound margins, reducing loss of intraocular fluid and pressure. The NEI seeks licensees or collaborative co-development of this invention so that it can be commercialized.
Researchers at the National Eye Institute have developed a new cytokine therapy that delivers functional interleukin 34 (IL-34) to the retina for treating ocular inflammatory diseases – such as uveitis and degenerative retinal diseases. Intraocular delivery of IL-34 protein or IL-34 gene expression system can effectively prevent retinal inflammation. Thus, it may be a promising strategy to produce long-lasting effects in suppressing abnormal retinal inflammation and preventing photoreceptor death.
Regulatory B-cells (Breg) play an important role in reducing autoimmunity and reduced levels of these cells are implicated in etiology of several auto-inflammatory diseases. Despite their impact in many diseases, their physiological inducers are unknown. The National Eye Institute seeks parties interested in licensing or collaborative research to co-develop a process for the production of regulatory B-Cells for use in auto-immune indications.